TACI Ig融合蛋白抑制TLR4/MyD88/NF-κB通路减轻IgA肾病大鼠肾损伤

IF 0.8 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases Pub Date : 2024-12-19 DOI:10.52547/a63wam88

引用次数: 0

摘要

前言：评价TACI融合蛋白（TACI- ig）对大鼠IgA肾病（IgAN）的影响，探讨其机制及其与TLR4/MyD88/NF-κB通路的关系。方法：将SD大鼠分为对照组、模型组、TACI-Ig低剂量组（TACI-Ig- l）、中剂量组（TACI-Ig- m）、高剂量组（TACI-Ig- h）和醋酸泼尼松组（PAT） 6组。对照组和模型组给予生理盐水注射，TACI-Ig组分别给予7.18、14.36、28.72 mg/kg TACI-Ig。PAT组采用醋酸泼尼松预处理。8周后，测定肾重/体重比、24小时尿蛋白（24 h UP）、血清肌酐（SCr）、血尿素氮（BUN）水平。此外，采用ELISA法检测B细胞活化因子（BAFF）、APRIL、Gd-IgA1的浓度。采用western blot （WB）和RT-qPCR检测各组肾组织TLR4、MyD88、NF-κB的表达水平。结果。肾功能评估显示，IgAN模型组小鼠24 h UP、SCr、BUN升高，血清BAFF、APRIL、Gd-IgA1水平升高，TLR4/MyD88/NF-κB蛋白表达升高。TACI-Ig治疗显著降低了IgAN大鼠的蛋白尿、SCr、BUN、BAFF、APRIL和Gd-IgA1水平。病理上，TACI-Ig改善肾小球系膜沉积和纤维化。抑制TLR4/MyD88/NF-κB蛋白表达，具有抗炎和免疫调节作用。结论：TACI-Ig通过减少炎症浸润和IgA沉积，抑制TLR4/MyD88/NF-κB通路，减轻IgAN大鼠肾损伤，为开发IgAN的有效治疗方法提供数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TACI Ig Fusion Protein Inhibits

Introduction: To evaluate the impact of TACI fusion protein (TACI-Ig)

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Iranian journal of kidney diseases UROLOGY & NEPHROLOGY-

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Iranian Journal of Kidney Diseases (IJKD), a peer-reviewed journal in English, is the official publication of the Iranian Society of Nephrology. The aim of the IJKD is the worldwide reflection of the knowledge produced by the scientists and clinicians in nephrology. Published quarterly, the IJKD provides a new platform for advancement of the field. The journal’s objective is to serve as a focal point for debates and exchange of knowledge and experience among researchers in a global context. Original papers, case reports, and invited reviews on all aspects of the kidney diseases, hypertension, dialysis, and transplantation will be covered by the IJKD. Research on the basic science, clinical practice, and socio-economics of renal health are all welcomed by the editors of the journal.